Loading patent…
AssigneeKyungpook National University Industry-Academic Cooperation Foundation
InventorsJu-Ock Nam, Jung-Eun Kim, Ha-Won Jeong, Sung-Jin Lee, Byung-Heon Lee, Je-Yong Choi, Rang-Woon Park, Jae-Yong Park, In-San Kim, Hye-Nam Son
Estimating the term…
The present invention relates to the novel use of a polypeptide comprising an isolated polypeptide comprising EMI domain, four fas-1 domains and RGD motif of βig-h3. More particularly, the invention relates to a method for the inhibition of the adhesion, migration and/or proliferation of endothelial cells, and/or for the inhibition of angiogenesis, using the isolated polypeptide comprising EMI domain, four fas-1 domains and RGD motif of βig-h3, or functional equivalents thereof. Furthermore, the invention provides a method for treating or preventing angiogenesis-related diseases, using the polypeptide.
A method for inhibiting the adhesion, migration and/or proliferation of endothelial cells, which comprises administering to a subject in need thereof an effective amount of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3.
A method for inducing the apoptosis of endothelial cells, which comprises administering to a subject in need thereof an effective amount of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3.
A method for inhibiting angiogenesis, which comprises administering to a subject in need thereof an effective amount of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3.
A method for the treatment or prevention of angiogenesis-related diseases, which comprises administering to a subject in need thereof an effective amount of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3.
A pharmaceutical composition for the inhibition of angiogenesis, which comprises as an active ingredient of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3.
A pharmaceutical composition for the treatment or prevention of angiogenesis-related diseases, which comprises as an active ingredient of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3.
Use of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3, for the preparation of a pharmaceutical agent of inhibiting the adhesion, migration and/or proliferation of endothelial cells.
Use of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3, for the preparation of a pharmaceutical agent of inducing the apoptosis of endothelial cells.
Use of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3, for the preparation of an angiogenesis-inhibiting agent.
Use of an isolated polypeptide comprising EMI domain, all of four fas-1 domains and RGD motif of βig-h3, for the preparation of a therapeutic or preventive agent for angiogenesis-related diseases.
Dependencies are inferred from the claim text.